| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514500100 | Growth hormone (GH) or derivative utilizing | 7 |
| 20110105390 | SELECTION AND TREATMENT OF PATIENTS SUFFERING FROM WASTING - The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions. | 05-05-2011 |
| 20120035101 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME - Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed. | 02-09-2012 |
| 20140135260 | Ghrelin Analogs - The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof. | 05-15-2014 |
| 20140323396 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 10-30-2014 |
| 20150306182 | FAT LOSS COMPOSITION - Disclosed is a fat loss composition comprising a) a prostaglandin F2alpha analogue, such as cloprostenol, or a pharmaceutically acceptable ester or salt thereof; and b) amino acids 176-191 of human growth hormone. Use of the composition in weight loss, weight management and/or slimming is described. | 10-29-2015 |
| 20160136178 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME - Provided are immediate or prolonged administration of certain potassium ATP (K | 05-19-2016 |
| 20180021344 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | 01-25-2018 |
